EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Intranasal bleomycin sclerotherapy versus local Avastin® therapy as an adjunct to laser treatment for epistaxis in hereditary hemorrhagic telangiectasia

Karin P. Q. Oomen, Volkert B. Wreesmann, Benjamin J. Waner, Stefan Waner, Milton Waner, Teresa M. O

Discover Medicine · 02.08.2026 · 3 (1)

DOI: 10.1007/s44337-026-00645-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Discover Medicine, online erschienen am 02.08.2026. Verfasst von Karin P. Q. Oomen und 5 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Oomen, K. P. Q., Wreesmann, V. B., Waner, B. J., Waner, S., Waner, M., & O, T. M. (2026). Intranasal bleomycin sclerotherapy versus local Avastin® therapy as an adjunct to laser treatment for epistaxis in hereditary hemorrhagic telangiectasia. Discover Medicine, 3(1). https://doi.org/10.1007/s44337-026-00645-1

Vancouver

Oomen KPQ, Wreesmann VB, Waner BJ, Waner S, Waner M, O TM. Intranasal bleomycin sclerotherapy versus local Avastin® therapy as an adjunct to laser treatment for epistaxis in hereditary hemorrhagic telangiectasia. Discover Medicine. 2026;3(1). doi:10.1007/s44337-026-00645-1

BibTeX
@article{Oomen2026,
  author = {Oomen, Karin P. Q. and Wreesmann, Volkert B. and Waner, Benjamin J. and Waner, Stefan and Waner, Milton and O, Teresa M.},
  title = {Intranasal bleomycin sclerotherapy versus local Avastin® therapy as an adjunct to laser treatment for epistaxis in hereditary hemorrhagic telangiectasia},
  journal = {Discover Medicine},
  year = {2026},
  volume = {3},
  number = {1},
  doi = {10.1007/s44337-026-00645-1}
}
Kostenlos starten →